header
Image from OpenLibrary

Comparative pharmaceutical study on different dosage forms used on ocular drug delivery / Enas Abdelmoneim M. R. Afify ; Supervised Magdy Ibrahim Mohamed , Mary Kamal Gad

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Enas Abdelmoneim M. R. Afify , 2018Description: 236 P. : charts , facsimiles ; 25cmOther title:
  • دراسه صيدليه مقارنه علي الصياغات الصيدليه المختلفه التي تستخدم في التوصيل الدوائي للعين [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics Summary: Glaucoma is an ophthalmic disease associated with an increase in the intra-ocular pressure (IOP). Persistent high IOP accompanied with glaucoma can damage the optic nerve with time. Untreated glaucoma may lead to blindness within few years.The anti-glaucoma therapy requires continued administration of medicines for long time and so, sustained release systems are needed to help in keeping constant drug levels at the site of action and enhancing patient compliance through decreasing the dosing frequency. Dorzolamide hydrochloride (DH) is a carbonic anhydrase inhibitor used in treatment of glaucoma through decreasing the production of aqueous humor. DH is 20 times more active than acetazolamide in lowering the IOP when applied topically. The drug is available in the market as eye drops; Trusopt® (Merck, N.J., USA) containing 2% DH in the form of aqueous solution buffered at pH 5.6. Trusopt® is administered three times a day to achieve a sufficient control over the IOP but this can exaggerate any possible side effect and affect the patient compliance. Reformulation of DH in the form of sustained nanoparticles or ocuserts may enhance patient compliance, pharmacokinetic and pharmacological behavior
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2018.En.C (Browse shelf(Opens below)) Not for loan 01010110076764000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.Ph.D.2018.En.C (Browse shelf(Opens below)) 76764.CD Not for loan 01020110076764000

Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Glaucoma is an ophthalmic disease associated with an increase in the intra-ocular pressure (IOP). Persistent high IOP accompanied with glaucoma can damage the optic nerve with time. Untreated glaucoma may lead to blindness within few years.The anti-glaucoma therapy requires continued administration of medicines for long time and so, sustained release systems are needed to help in keeping constant drug levels at the site of action and enhancing patient compliance through decreasing the dosing frequency. Dorzolamide hydrochloride (DH) is a carbonic anhydrase inhibitor used in treatment of glaucoma through decreasing the production of aqueous humor. DH is 20 times more active than acetazolamide in lowering the IOP when applied topically. The drug is available in the market as eye drops; Trusopt® (Merck, N.J., USA) containing 2% DH in the form of aqueous solution buffered at pH 5.6. Trusopt® is administered three times a day to achieve a sufficient control over the IOP but this can exaggerate any possible side effect and affect the patient compliance. Reformulation of DH in the form of sustained nanoparticles or ocuserts may enhance patient compliance, pharmacokinetic and pharmacological behavior

Issued also as CD

There are no comments on this title.

to post a comment.